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Abstract
Background: FLASH is a huge nuclear protein involved in various cellular functions such as apoptosis signalling,
NF-B activation, S-phase regulation, processing of histone pre-mRNAs, and co-regulation of transcription. Recently,
we identified FLASH as a co-activator of the transcription factor c-Myb and found FLASH to be tightly associated
with active transcription foci. As a huge multifunctional protein, FLASH is expected to have many interaction
partners, some which may shed light on its function as a transcriptional regulator.
Results: To find additional FLASH-associated proteins, we performed a yeast two-hybrid (Y2H) screening with
FLASH as bait and identified the SUMO E3 ligase PIAS1 as an interaction partner. The association appears to
involve two distinct interaction surfaces in FLASH. We verified the interaction by Y2H-mating, GST pulldowns, co-IP
and ChIP. FLASH and PIAS1 were found to co-localize in nuclear speckles. Functional assays revealed that PIAS1
enhances the intrinsic transcriptional activity of FLASH in a RING finger-dependent manner. Furthermore, PIAS1 also
augments the specific activity of c-Myb, and cooperates with FLASH to further co-activate c-Myb. The three
proteins, FLASH, PIAS1, and c-Myb, are all co-localized with active RNA polymerase II foci, resembling transcription
factories.
Conclusions: We conclude that PIAS1 is a common partner for two cancer-related nuclear factors, c-Myb and
FLASH. Our results point to a functional cooperation between FLASH and PIAS1 in the enhancement of c-Myb
activity in active nuclear foci.
Background
The FLICE associated huge protein (FLASH) has been
reported to be a potential prognostic marker in cases of
acute lymphoblastic leukaemia [1] and recently also
detected as a novel partner gene of MLL rearrangement
in acute myeloid leukaemia [2]. FLASH was originally
identified as a caspase-8 interacting protein and was
reported to be necessary for the activation of caspase-8
in Fas-mediated apoptosis [3]. More recent findings sug-
gest that FLASH may have a role in apoptosis by being
part of a nuclear signalling pathway involving the PML
nuclear body component Sp100 [4]. Consistent with a
nuclear function, FLASH was found localized mainly in
nuclear speckles, partially co-localizing with Cajal bodies
and PML nuclear bodies [4-6]. Nevertheless, FLASH
may still have a temporary cytoplasmic function as it
appears to shuttle from the nucleus to the cytoplasm in
a caspase-dependent process upon CD95 activation [4].
Interestingly, functional studies have shown that apart
from its role as a pro-apoptotic protein, FLASH is also
involved in control of cell cycle progression. Down-
regulation of FLASH reduced histone gene transcription
and caused a block of cells within S-phase of the cell
cycle [7]. This function of FLASH was recently
appointed to its association with Histone Locus Bodies
(HLBs) [8]. FLASH is essential for 3’ processing of his-
tone pre-mRNAs taking place in HLBs [9], and a disrup-
tion of these bodies leads to a cell-cycle arrest [10].
Importantly, the role of FLASH in transcriptional
control is not limited to histones. FLASH appears to
have a cell type specific function as a regulator of ster-
oid hormone receptor signalling. FLASH causes down-
regulation of GR, PR and AR in a colon carcinoma cell
line [11,12], but activates GR and MR in hippocampal
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neurons [13]. We have earlier demonstrated a new func-
tion of FLASH as a co-activator of the transcription fac-
tor c-Myb [6]. We showed that FLASH enhanced the
expression of the endogenous c-Myb target gene mim-1
and knock-down of FLASH resulted in a reduction in
expression of c-Myb target genes in haematopoietic cells
[6]. All these diverse roles point to FLASH as being a
multifunctional nuclear protein.
The transcription factor c-Myb plays a central role in
the regulation of cell growth and differentiation in hae-
matopoietic cells [14]. It operates as a regulator of stem
and progenitor cells in the bone marrow, as well as in
colonic crypts and in a neurogenic region of the adult
brain [15]. In the avian system, leukaemia is induced by
truncated and mutated forms of v-Myb encoded by two
types of retrovirus strains (AMV and E26). The link
between MYB aberrations and human cancer was
recently strengthened by the detection of duplications
and translocations of the MYB gene in T cell acute lym-
phoblastic leukaemia [16,17]. Moreover, Stenman and co-
workers reported that a MYB-NFIB fusion is a hallmark
of adenoid cystic carcinomas (ACC) of the breast, head
and neck, and that deregulation of the expression of
MYB is a key oncogenic event in the pathogenesis of
ACC [18]. The emerging picture is that the level of c-
Myb seems to be critical for proper functioning of the
haematopoietic system and in other tissues where c-Myb
plays a key role, and only a modest deregulation may
have dramatic biological effects. The activity of c-Myb is
controlled by the expression levels of the protein, through
mechanisms where miRNAs seem to play a major role
[18,19]. In addition, c-Myb is also modulated by post-
translational modifications as well as by protein-protein
interactions. c-Myb is phosphorylated at several sites by
different kinases [14,20-23], sumoylated at two lysine resi-
dues in the C-terminal regulatory domain [24-26] and
acetylated by the co-activator CBP/p300 [27,28]. More-
over, different factors have been reported to interact with
c-Myb regulating its activity; besides FLASH [6], we have
also earlier identified another co-activator of c-Myb, the
chromatin remodelling factor Mi-2a, shown to regulate
endogenous c-Myb target genes [29]. Recently, we also
showed that interaction with SUMO is involved in regu-
lation of c-Myb activity [30].
The protein inhibitor of activated STAT (PIAS) family
of proteins consists of PIAS1, PIAS2 (PIASx), PIAS3
and PIAS4 (PIASy) that share a high degree of sequence
conservation (reviewed in [31,32]), and hZimp7 and
hZimp10 with more limited sequence similarity [33,34].
In addition to their function as negative regulators of
STAT signalling, PIAS proteins can also act as SUMO
E3 ligases, enhancing sumoylation of target proteins
[31,32]. This activity is dependent on a RING finger
domain present in PIAS proteins [31,32,35]. Since
sumoylation of transcriptional regulators often leads to
inhibition of their activity [36,37], PIAS proteins have
been described as negative regulators of transcription.
However, PIAS proteins are also known to act as co-
activators [31]. It has also been reported that PIAS pro-
teins can bind to and alter the subcellular localization of
different proteins [38-40]. Interestingly, these activities
of PIAS proteins as modulators of transcription may
occur both in SUMO-dependent or independent man-
ners [32].
In an effort to better understand FLASH action, we
searched for new interaction partners for FLASH. In a
yeast two-hybrid screening using FLASH as bait, we
identified PIAS1 as a binding partner. Here we show
that PIAS1 enhances FLASH activity and its ability to
co-activate c-Myb. PIAS1 together with FLASH is able
to further enhance the transcriptional activity of c-Myb.
Consistent with the up-regulation of activity of both
FLASH and c-Myb, all three proteins, FLASH, c-Myb
and PIAS1, are co-localized in active RNA polymerase II
foci. These results suggest that FLASH and PIAS1 coop-
erate in enhancing c-Myb transcriptional activity in foci
that resemble transcription factories.
Results
FLASH interacts with PIAS1
To advance our understanding of FLASH function, we
performed a yeast two-hybrid (Y2H) screening with
FLASH as bait, using a human bone marrow cDNA
library (Clontech). Due to the high level of autoactiva-
tion of full-length FLASH, even when using the centro-
meric low copy vector pDBT, we selected as bait a
C-terminal fragment of FLASH encoding amino acid
residues 1508-1982 (FLASH-D). This part of the protein
contains the DED-recruiting domain (DRD) [3] and also
includes the region that interacts with c-Myb [6]. The
N-terminal border of this fragment was placed in a ser-
ine/proline-rich area, predicted to be located between
globular domains http://globplot.embl.de. Among the
positive clones obtained in the Y2H screening we identi-
fied the SUMO E3 ligase PIAS1 (amino acids 1-501).
The interaction between FLASH-D and PIAS1 was veri-
fied by retransformation in yeast and testing for activa-
tion of the HIS3 (Figure 1A) and LacZ (not shown)
reporter genes. Further Y2H mating assays using
FLASH-ΔD (amino acid residues 1- 1507) as bait indi-
cated that PIAS1[1-501] did not interact with other
regions of FLASH (data not shown). On the other hand,
full length PIAS1 was able to interact not only with
FLASH-D, but also with the N-terminal fragment of
FLASH (amino acid residues 1-304), FLASH-A (Figure
1B and 1C). This indicates that the C-terminal part of
PIAS1 probably represents a second interaction surface,
associating with the N-terminal part of FLASH.
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Figure 1 FLASH and PIAS1 interact and co-localize in nuclear speckles. (A) AH109 yeast cells were transformed with bait vector pDBT or
pDBT-FLASH-D and mated with the yeast strain Y187 pretransformed with prey vector pGADT7 or pGADT7-PIAS1[1-501]. Interaction was verified
by activation of the HIS3 reporter gene (SC-L-W-H). Each mating was performed in duplicate. (B) AH109 yeast cells were transformed with bait
vector pDBT or pDBT-FLASH-A/B/C/D/E and mated with Y187 pretransformed with prey vector pGADT7 or pGADT7-PIAS1. Interaction was
verified by activation of the HIS3 reporter gene (SC-L-W-H). Each mating was performed in duplicate. (C) Schematic overview of the regions of
FLASH used in yeast two-hybrid assays. Abbreviation; DRD = DED-recruiting domain [3]. A: amino acids 1-304, B: 305-867, C: 868-1507, D: 1508-
1982, E: 1814-1982. (D) GST, GST-FLASH-D and GST-FLASH-A were incubated with lysate from COS-1 cells transfected with full-length 3×FLAG-
tagged PIAS1. PIAS1 was detected by an anti-FLAG antibody. 5% of the input (total cell extract) used for the pulldown was loaded as reference.
(E) Lysates from COS-1 cells transfected with GFP-FLASH and 3×FLAG-PIAS1 or empty vector, were immunoprecipitated with anti-FLAG antibody
or an irrelevant antibody (anti-GST), and the precipitates were analyzed by immunoblotting using anti-GFP (FLASH) and anti-FLAG (PIAS1) for
detection. 5% (PIAS1) or 10% (FLASH) of the input used for immunoprecipitation was loaded as reference. ProtG, protein G-Sepharose beads
only. (F) HEK 293 cells were transfected with plasmids expressing 3×FLAG-PIAS1 and a Gal4p-DBD-FLASH fusion protein. Occupancies of PIAS1
on the 5×GRE promoter and on the NCOA5 intron were analysed using ChIP-qPCR. (G) CV-1 cells were transfected with plasmids encoding
HA-PIAS1 and 3×FLAG-FLASH, and analysed with indirect immunofluorescence and confocal microscopy. PIAS1 was detected with rabbit anti-HA
antibody and Alexa Fluor 488 goat anti-rabbit IgG. FLASH was detected with mouse anti-FLAG antibody and Alexa Fluor 633 goat anti-mouse
IgG1. The merged image is shown in the right panel.
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The interaction between FLASH and PIAS1 was con-
firmed by GST pulldown assays. Specific binding was
observed when GST-FLASH-D and GST-FLASH-A was
incubated with lysates from COS-1 cells transfected
with full-length PIAS1 (Figure 1D). These results sup-
port the data obtained from the Y2H assays, confirm-
ing the interaction between PIAS1 and both N- and
C-terminal regions of FLASH. A third line of evidence
for the interaction was provided by co-immunoprecipi-
tation assays using lysates from COS-1 cells transfected
with full-length FLASH and PIAS1. As shown in Figure
1E, FLASH was co-immunoprecipitated with FLAG-
tagged PIAS1 using anti-FLAG antibodies, but not with
anti-GST antibodies or Sepharose beads. Finally, we
took advantage of a reporter cell line with an inte-
grated Gal4p-responsive promoter to study this inter-
action in a chromatin context [41]. Using chromatin
immunoprecipitation (ChIP) we did not see any enrich-
ment of PIAS1 on the promoter when expressed alone
(Figure 1F). However, when transfected together with
FLASH fused to a Gal4p DNA-binding domain, PIAS1
was efficiently recruited to the GAL promoter through
Gal-FLASH. This was not seen for the neighbouring
NCO5A control promoter (Figure 1F). Altogether this
shows that PIAS1 and FLASH interact, also in a chro-
matin context.
FLASH and PIAS1 co-localize in nuclear speckles
Both FLASH and PIAS1 have been found localized
mainly in nuclear speckles in several cell lines
[4-6,39,42,43]. If an interaction between FLASH and
PIAS1 exists, we would expect, at least, a partial co-
localization of the speckles in which these proteins are
found. To examine this, we transfected CV-1 cells with
HA-tagged FLASH and FLAG-tagged PIAS1 and ana-
lyzed their subcellular localization by immunofluores-
cence and confocal microscopy. Consistent with
previous reports [4-6,42-44], we found that both PIAS1
and FLASH were localized in nuclear foci (Figure 1G).
Whereas PIAS1 was distributed both in the nucleoplasm
and in nuclear speckles (Figure 1G, left panel) and was
found in a larger number of speckles than FLASH, it is
evident that the majority of the FLASH foci co-localized
with PIAS1 foci. These observations clearly support the
notion that FLASH and PIAS1 proteins are able to co-
localize in mammalian cells, consistent with their
mutual binding affinities.
The function of PIAS1 in relation to FLASH
In order to determine the functional consequences of
the PIAS1-FLASH interaction, we addressed two main
questions: 1) Whether PIAS1 enhances FLASH sumoyla-
tion and 2) whether PIAS1 modulates the intrinsic
transactivation function of FLASH.
PIAS1 is a SUMO E3 ligase, and since it interacts with
FLASH, we first analyzed whether FLASH sumoylation
is enhanced as a result of this interaction. We have pre-
viously shown that FLASH interacts with Ubc9 and
becomes sumoylated on lysine 1813 [45]. We therefore
examined whether PIAS1 stimulates SUMO-conjugation
on this lysine. As shown in Figure 2A (left panel), a
slower migrating band at about 100 kD appeared when
co-transfecting FLASH-D with PIAS1 and SUMO-1.
This band disappeared with the K1813R mutant, as
expected for FLASH being sumoylated on this lysine.
The effects observed when co-transfecting with GFP-
SUMO-1 (Figure 2A, right panel) corroborated this
interpretation. GFP-SUMO-1 both shifts the equilibrium
towards sumoylated species and as a result induces new
GFP-SUMO-1-FLASH bands (GS-F) migrating more
slowly than the SUMO-induced shift (S-F). As can be
seen in the right panel, two of the bands corresponding
to SUMO-1- (S-F) and GFP-SUMO-1-modified FLASH
(GS-F) disappeared with the K1813R mutant (Figure
2A). This supports the notion that FLASH is modified
by SUMO on K1813. The remaining bands indicate that
FLASH is sumoylated on at least one additional lysine
residue as previously reported [45]. Taken together
PIAS1 seems to function as a SUMO E3 ligase enhan-
cing the sumoylation of FLASH.
Since PIAS proteins appear to operate as transcrip-
tional co-regulators, being either activating or repressive
(reviewed in [31,32]), we investigated whether PIAS1
would modulate the intrinsic transactivation function of
FLASH. We performed a Gal4-tethering assay and mea-
sured the activity of Gal4p-DBD-FLASH in the absence
and presence of co-transfected PIAS1. Interestingly,
PIAS1 enhanced the transactivation function of FLASH
about threefold in this assay (Figure 2B). No alteration
of the control Gal4p-DBD activity was observed, con-
firming the specificity of PIAS1 action on FLASH activ-
ity. To examine whether the PIAS1 SUMO E3 ligase
activity was required for the response, we performed the
same type of experiment using a PIAS1 RING finger
mutant that is unable to stimulate sumoylation. The
RING finger mutant did not enhance the transcriptional
activity of FLASH (Figure 2B). Notably, this observation
suggests that PIAS1 E3 ligase activity is required for
enhancing the intrinsic activity of FLASH. To address
whether the presumed PIAS1 sumoylation target was
FLASH, we included a Gal4p-DBD-FLASH fusion pro-
tein in which the major sumoylation site was mutated
(K1813R) [45]. PIAS1 still activated FLASH-KR but to a
lesser extent than FLASH wild-type (Figure 2B). As
expected, the PIAS1 RING finger mutant did not
enhance the FLASH-KR activity (Figure 2B). None of
these effects were due to altered interactions. As seen in
Figure 2C, PIAS1 with the RING finger mutated bound
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Figure 2 PIAS1 functions as a SUMO E3 ligase and co-activator of FLASH. (A) CV-1 cells were transfected with plasmids encoding 3×FLAG-
FLASH-D or 3×FLAG-FLASH-D-KR (0.5 μg), (His)6-SUMO-1 (0.5 μg) and increasing amounts (0.5, 1.0, 1.5 μg) of HA-PIAS1 (left panel). Likewise, CV-1
cells were transfected with the same plasmids, except for (His)6-SUMO-1 which was exchanged with 0.5 μg GFP-SUMO-1 (right panel). Whole cell
extracts were analyzed by SDS-PAGE and immunoblotting using anti-FLAG antibody for the detection of FLASH, as well as anti-PIAS1 and anti-
GAPDH antibodies. Arrows indicate non-sumoylated FLASH (F), sumoylated FLASH (S-F), and FLASH sumoylated with GFP-SUMO1 (GS-F). (B) CV-1
cells were transfected with plasmids encoding Gal4p-DBD-FLASH wild-type, K1813R mutant (FLASH-KR), or Gal4p-DBD only (0.4 μg) in absence
and presence of PIAS1 wild-type or PIAS1 RING finger mutant (PIAS1-C350S) (0.2 μg) in combination with a Gal4p-driven SNRPN promoter
reporter construct. The results are presented as relative luciferase units (RLU) and represent the mean RLU ± SEM of three independent assays
performed in triplicates. (C) GST, GST-FLASH-D wild-type (GST-FLASH) and K1813R (GST-FLASH KR) were incubated with lysates from COS-1 cells
transfected with full-length 3×FLAG-tagged PIAS1 wild-type or RING finger mutant (C346S/C351S/H353A/C356S). PIAS1 was detected by an anti-
FLAG antibody. 5% of the input (total cell extract) used for the pulldown was loaded as reference. The amount of GST and GST fusion proteins
was evaluated with Ponceau S red staining of the membrane after immunoblotting. */**, GST or GST-FLASH-D, respectively.
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FLASH with the same efficiency as PIAS1 wild-type.
Similarly, the K1813R mutation in the SUMO acceptor
lysine of FLASH had no effect on the interaction with
PIAS1, wild-type or RING finger mutant (Figure 2C).
Taken together, these data imply that PIAS1 acts as a
co-activator of FLASH in a RING finger-dependent
manner, and that sumoylation of FLASH is required for
full enhancement of FLASH activity.
Regulation of c-Myb activity by PIAS1 and FLASH
Our previous studies had shown that FLASH binds to c-
Myb and enhances c-Myb dependent target gene activa-
tion [6]. Having found that PIAS1 enhances the activity
of FLASH (Figure 2), we next asked whether the inter-
action of PIAS1 with FLASH had any influence on the
activity of c-Myb. Reporter assays showed that PIAS1
enhanced c-Myb activity to about the same degree as
FLASH (Figure 3A). Moreover, PIAS1 and FLASH
together enhanced c-Myb dependent transcription even
further, implying that they cooperate to increase c-Myb
dependent activity (Figure 3A). In order to determine if
these results could be extended to a more physiological
system, we also analyzed the expression of an endogen-
ous c-Myb target gene, mim-1, in the haematopoietic
cell line HD11. As shown in Figure 3B, both FLASH
and PIAS1 enhanced c-Myb-dependent expression of
mim-1, and the co-expression of both proteins induced
a further increase in the expression levels of mim-1,
very similar to what was observed in the reporter assays
(Figure 3A). These results indicate that PIAS1 and
FLASH cooperate in the enhancement of c-Myb tran-
scriptional activity.
For PIAS1-mediated co-activation of FLASH we found
that PIAS1 required an intact SUMO E3 ligase activity
(Figure 2). Therefore, we asked whether the PIAS1-
mediated activation of c-Myb was dependent on c-Myb
sumoylation. c-Myb is sumoylated in lysine 503 and 527
[24,25]. The mutation of both these lysines (c-Myb-
2KR) completely abolishes c-Myb sumoylation and cre-
ates a significantly more active factor. We found that
Figure 3 Regulation of c-Myb activity by PIAS1 and FLASH. (A) CV-1 cells were transfected with the c-Myb-responsive 3×MRE(GG)-MYC
reporter plasmid (0.2 μg) and plasmids encoding c-Myb, FLASH and PIAS1 as indicated (each 0.2 μg). (B) HD11 cells were transfected with
plasmids encoding c-Myb, FLASH and PIAS1 as indicated. c-Myb activation of the target gene mim-1 was measured by quantitative real-time PCR
with primers specific for mim-1 and HPRT. The results are presented as mim-1 expression relative to HPRT expressions ± SEM. (C) CV-1 cells were
transfected with the c-Myb-responsive 3×MRE(GG)-MYC reporter plasmid (0.2 μg) and plasmids encoding c-Myb-2KR, FLASH and PIAS1 as
indicated (0.2 μg each). The results in (A) and (C) are presented as relative luciferase units (RLU) and represent the mean RLU ± SEM of three
independent assays performed in triplicates. For each experiment Western immunoblotting is shown below.
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PIAS1 still activated the SUMO-negative c-Myb-2KR to
about the same degree as wild-type c-Myb (Figure 3C).
The observation that PIAS1 activates c-Myb indepen-
dent of SUMO-status is consistent with an earlier report
stating that PIAS1 does not appear to have any signifi-
cant effect on the sumoylation of c-Myb [46]. Taken
together, these results suggest that even though an
intact PIAS1 E3 RING finger domain is required for
enhancement of FLASH transactivation, PIAS1-mediated
co-activation of c-Myb seems to be independent on c-
Myb sumoylation.
To further understand the role of PIAS1 in the enhance-
ment of FLASH-mediated co-activation of c-Myb, we
tested whether PIAS1 and c-Myb interact directly. A Y2H
mating assay indicated that c-Myb binds full-length
PIAS1. Interestingly, it does not appear to bind the shorter
version PIAS1[1-501] (Figure 4A), suggesting that the
C-terminal 150 amino acid residues of PIAS1 are neces-
sary for its c-Myb interaction. We also used the above-
mentioned reporter cell line and ChIP as an independent
assay of this interaction on chromatin and observed that
PIAS1 was recruited to the reporter promoter only in the
presence of c-Myb (Figure 4B). This was not caused by
PIAS1 affecting the Myb ChIP, as c-Myb co-immunopre-
cipitated the promoter just as efficiently when transfected
alone as when co-transfected with PIAS1 (Figure 4C).
An interaction between c-Myb and PIAS1 in addition
to the one between PIAS1 and FLASH may stabilize the
c-Myb-FLASH interaction. Given that a triple complex
is the most active form, this may explain why PIAS1,
together with FLASH, further enhances the transcrip-
tional activity of c-Myb (Figure 3). To analyze this, we
studied the effect of both PIAS1 full length and the
shorter version PIAS1[1-501] in a c-Myb dependent
reporter assay. As previously observed, both FLASH and
PIAS1 individually activated c-Myb. On the other hand,
PIAS1[1-501] had only a slight effect on the activity of
c-Myb (Figure 4D), consistent with lost c-Myb binding
properties. However, in the presence of co-transfected
FLASH, PIAS1[1-501] also became able to enhance the
transcriptional activity of c-Myb, probably through the
enhancement of FLASH co-activation. Nevertheless,
when full length PIAS1 is co-expressed, the transactiva-
tion activity of c-Myb was further enhanced, supporting
our hypothesis that the triple complex c-Myb-FLASH-
PIAS1 could represent the full complex needed for max-
imal activity. Notably, the PIAS1 RING finger mutant,
that did not enhance FLASH intrinsic activity (Figure
2B), resembled PIAS1[1-501] in its fairly small enhance-
ment of c-Myb transcriptional activity when co-
expressed with FLASH (Figure 4D).
Finally, we reasoned that if PIAS1 acts as one of the
co-activators of c-Myb, one would expect to see an
effect on endogenous target genes of c-Myb if the level
of PIAS1 was significantly reduced. To address this, we
specifically knocked down PIAS1 in the c-Myb expres-
sing human erythroleukaemia K562 cells and monitored
the expression of two established c-Myb target genes,
MYC and LMO2 [47,48]. As the mRNA of PIAS1
dropped to only ~14% of its normal level, the two target
genes MYC and LMO2 were both significantly down-
regulated as a consequence of PIAS1 knock-down
(Figure 4E). Both MYC and LMO2 have been verified to
be responsive to c-Myb knock-down in K562 cells ([49]
and unpublished results). Taken together, these observa-
tions support our hypothesis that PIAS1 cooperates with
c-Myb in a positive fashion to activate the transcription
of at least a subset of endogenous c-Myb target genes.
FLASH, PIAS1 and c-Myb are all co-localized in active RNA
polymerase II foci
FLASH is associated with active RNA polymerase II foci,
in which we have found FLASH and c-Myb to be co-
localized [6]. Since PIAS1 is involved in co-activation of
both FLASH and c-Myb, we examined whether PIAS1
also co-localizes with FLASH and c-Myb in these active
transcription foci. As shown in Figure 5A, co-transfected
FLASH and PIAS1 co-localized with active RNA poly-
merase II foci. When we analyzed the localization
of transfected c-Myb and PIAS1, we observed that
although these proteins can be found both in the
nucleoplasm and in speckles, they clearly co-localize in
some stronger foci. Moreover, these foci co-localize with
RNA pol II foci (Figure 5B). In conclusion, FLASH,
PIAS1 and c-Myb are all co-localized in active transcrip-
tion foci.
Discussion
FLASH and c-Myb are both cancer-related nuclear pro-
teins for which a better understanding of mechanism of
action is needed. In this work we have demonstrated a
novel link between these two factors through PIAS1.
We have earlier reported that FLASH directly interacts
with c-Myb and functions as a co-activator of c-Myb
[6]. Our search for additional interaction partners of
FLASH, led to the identification of PIAS1 as one of the
interaction partners of FLASH (Figure 1). Interestingly,
PIAS1 enhances the transactivation potential of FLASH
through a mechanism that requires the RING domain
and therefore presumably the E3 ligase activity of PIAS1
(Figure 2). Moreover, the two proteins both bind to
c-Myb and cooperate to enhance its transcriptional
activity (Figure 3 and 4). The fact that both FLASH and
PIAS1 bind c-Myb suggests the possible formation of a
tripartite FLASH-PIAS1-c-Myb complex reinforced
by several interaction surfaces, providing a strong
enhancing effect on c-Myb-mediated gene activation.
Supporting this hypothesis, mutation of the RING
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Figure 4 PIAS1 interacts with c-Myb on chromatin and activates the expression of c-Myb target genes. (A) AH109 yeast cells were
transformed with bait vector pDBT or pDBT-c-Myb and mated with the yeast strain Y187 pretransformed with pray vector pGADT7, pGADT7-
PIAS1[1-501] or pGADT7-PIAS1. Interaction was verified by activation of the HIS3 reporter gene (SC-L-W-H). Each mating was performed in
duplicate. HEK 293 cells were transfected with plasmids expressing 3×FLAG-PIAS1 and a Gal4p-DBD-c-Myb-HA fusion protein. Occupancies of (B)
PIAS1 and (C) c-Myb on the 5×GRE promoter and on the NCOA5 intron were analysed using ChIP-qPCR. (D) CV-1 cells were transfected with the
c-Myb-responsive 3×MRE(GG)-MYC reporter plasmid (0.2 μg) and plasmids encoding c-Myb, FLASH, PIAS1, PIAS1[1-501] or PIAS1[C350S] as
indicated (0.2 μg each). The results are presented as relative luciferase units (RLU) and represent the mean RLU ± SEM of three independent
assays performed in triplicates. (E) K562 cells were transfected with siRNAs directed against PIAS1. Effects of PIAS1 knock-down on the
endogenous c-Myb target genes MYC and LMO2 were measured by quantitative real-time PCR using specific primers for the target genes and
the reference genes ACTB and POLR2A. The results are presented as PIAS1, MYC or LMO2 expression (normalized for ACTB and POLR2A expression)
after PIAS1 knock-down relative to their expressions in the knock-down control. The results are presented as mean relative mRNA level ± SEM.
Statistical significance was calculated using the Student’s t-test (P-value indicated).
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Figure 5 FLASH, PIAS1 and c-Myb are all co-localized in active RNA polymerase II foci. (A) CV-1 cells were transfected with plasmids
encoding HA-PIAS1 and 3×FLAG-FLASH. Cells were analysed by indirect immunofluorescence and confocal microscopy. PIAS1 was detected with
rabbit anti-HA antibody and Alexa Fluor 488 goat anti-rabbit IgG (green signal). RNA polymerase II phosphorylated on Ser-5 in the CTD was
detected with a mouse monoclonal anti-pol II (8A7) IgM antibody and Alexa Fluor 546 goat anti-mouse IgM, specific for the IgM heavy chains
(red signal). FLASH was detected with mouse anti-FLAG antibody and Alexa Fluor 633 goat anti-mouse IgG1, specific for the IgG1 heavy chains
(blue signal). Double merged images are shown as indicated, and triple merged images are visualized in right panel (merge). (B) CV-1 cells were
transfected with plasmids encoding c-Myb-HA and FLAG-PIAS1. c-Myb was detected with rabbit anti-HA antibody and Alexa Fluor 488 goat anti-
rabbit IgG (green signal). Active RNA polymerase II was detected as in (A) (red signal). PIAS1 was detected with mouse anti-FLAG antibody and
Alexa Fluor 633 goat anti-mouse IgG1, specific for the IgG1 heavy chains (blue signal). Double merged images are shown as indicated, and triple
merged images are visualized in right panel (merge).
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domain of PIAS1 or using a truncated protein that do
not bind c-Myb, in combination with FLASH, showed a
decrease in the enhancement of c-Myb transcriptional
activity (Figure 4D). Furthermore, ChIP showed that
PIAS1 binds both c-Myb and FLASH supporting a triple
complex binding DNA. Finally, we found a close asso-
ciation of FLASH, PIAS1 and c-Myb within active tran-
scription foci (Figure 5), suggesting that FLASH, PIAS1
and c-Myb cooperate to recruit the RNA polymerase II
machinery to actively transcribed sites in the genome.
PIAS proteins are well known for their role as inhibi-
tors of STAT proteins and as SUMO E3 ligases
(reviewed in [31]). More recently, PIAS proteins have
been found to act as transcriptional co-regulators in sev-
eral systems, a function that may either be activating or
repressive, SUMO-dependent or SUMO-independent
(reviewed in [31,32]). These functions may also be
modulated by specific post-translational modifications
such as phosphorylation and methylation [50,51].
Hence, PIAS proteins emerge as sophisticated pleio-
trophic transcriptional regulators. In this study we have
identified PIAS1 as a novel co-regulator of both FLASH
and c-Myb, expanding the range of factors with which
PIAS1 physically and functionally interacts. In this
regard, our findings parallel the discovery of PIAS1
interacting with the haematopoietic transcription factor
GATA-3 where PIAS1 in Th2 cells was found to
potentiate GATA-3 mediated activation of cytokine
gene promoters [52]. Another interesting parallel is the
PIAS3-mediated co-activation of Smad3, where PIAS3
was shown to enhance the transcriptional activity of
Smad3 by forming a ternary complex with the co-activa-
tor p300 [53]. Like in the present study on PIAS1,
PIAS3-mediated co-activation of Smad3 was dependent
on an intact RING domain and thus presumably SUMO
E3 ligase activity. The detailed mechanism underlying
the PIAS1-mediated co-activation of c-Myb is not
known, but a role in recruitment is a reasonable
assumption. The most obvious hypothesis is that c-Myb
binds the promoter of a specific target gene, causing
FLASH and PIAS1 to be recruited (Figure 1F and 4B),
where PIAS1 functions as a bridge between c-Myb/
FLASH and other parts of the transcriptional apparatus,
such as p300, general transcription factors or RNA poly-
merase II. Consistent with this is the observation that
PIAS1 interacts with the TATA-binding protein (TBP)
[54] and co-localizes with TBP [55] and RNA polymer-
ase II (Figure 5). In this scenario, PIAS1 may act as an
assembly factor for transcription complex formation.
It is well established that PIAS proteins act as SUMO
E3 ligases (reviewed in [31]). Despite the fact that
sumoylation in general is associated with a decrease in
the activity of transcription factors, several factors have
been reported to be activated by PIAS proteins in a E3-
ligase dependent way, as exemplified by Smad3, p53,
Rta, IE2 and androgen receptor (AR) [42,43,53,56-59].
FLASH also becomes sumoylated and we have identified
the K1813 as major sumoylation site, the modification
of which leads to a modest increase in FLASH activity
[45]. Based on this, we expected that the PIAS1-
mediated increase in FLASH transactivation occurred
through FLASH sumoylation. Consistent with this
hypothesis, mutation of the RING domain of PIAS1
abolished PIAS1-mediated increase in FLASH activity
(Figure 2B). Moreover, when FLASH and PIAS1 were
co-expressed, a significant increase in sumoylation of
FLASH K1813 was observed (Figure 2A). Still, PIAS1
enhanced the transactivation potential of a FLASH-
K1813R mutant, indicating that PIAS1-mediated sumoy-
lation of K1813 is unlikely to be the only mechanism of
PIAS1-mediated FLASH activation (Figure 2B). Even
though some of the remaining activation may be linked
to the existence of other weaker non-identified sumoyla-
tion sites in FLASH, or to sumoylation of some
unknown partner protein, we cannot exclude the possi-
bility of an alternative mechanism in which PIAS1 co-
activation occurs independently of PIAS1-mediated
sumoylation. An interesting possibility emerges if the
RING finger mutant not only affects the E3-ligase activ-
ity of PIAS1, but also its recruitment properties. In
the case for the Smad3-PIAS3-p300 interaction, the
SUMO E3 ligase activity of PIAS3 was necessary for co-
activation, even if the Smad3 SUMO-conjugation sites
were not required [53]. More important, the association
between PIAS3 and p300 was abolished by a RING fin-
ger mutant in PIAS3. If this is a property also of the
RING domain in PIAS1, a recruitment mechanism may
be more important for PIAS-mediated co-activation
than mechanisms dependent on SUMO-conjugation,
although both may contribute.
An attractive model of transcription is the transcrip-
tion factory model, according to which active tran-
scription occurs at discrete sites in the nucleus, termed
transcription factories, where multiple active RNA
polymerases are concentrated and anchored to a
nuclear substructure [60]. Apart from RNAPII, it is
not known what components are present in such fac-
tories, or what components are required for their for-
mation and function [60]. We have proposed FLASH
to be a component of at least a subgroup of transcrip-
tion factories [6]. The association of FLASH with
PIAS1 and our finding that PIAS1 co-localize with
FLASH and active RNA polymerase II, suggest that
PIAS1 may be an additional component of transcrip-
tion factories used by c-Myb to orchestrate activation
of its target genes.
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Conclusions
In conclusion, this study demonstrates that PIAS1 inter-
acts with FLASH and enhances its co-activation poten-
tial. Both FLASH and PIAS1 associate with c-Myb and
cooperate in enhancing c-Myb-dependent gene activa-
tion. FLASH, PIAS1 and c-Myb are all closely associated
with active RNA polymerase II in nuclear foci resem-
bling transcription factories. Hence, our study strength-
ens the link between two cancer-related nuclear factors,
c-Myb and FLASH, through their common interaction
with PIAS1.
Methods
Yeast two-hybrid screening and interaction assays
The Y2H screening with pDBT-FLASH-D as bait was
performed as described [45]. Positive clones were vali-
dated in the Y2H assay by retransformation and check-
ing for activation of the HIS3, ADE2 and LacZ reporter
genes. The identities of isolated clones were determined
by DNA sequencing. For verification of the interaction,
bait and prey plasmids were retransformed in AH109
and Y187 respectively, subjected to mating and subse-
quent reporter activation testing.
Plasmids
pDBT-FLASH-D was used as bait in the Y2H screening.
It encodes amino acids 1508-1982 of human FLASH
fused to Gal4p-DBD. pDBT-FLASH-A, -B, -C, D and -E
encode different FLASH fragments in fusion with
Gal4p-DBD (A; amino acids 1-304, B: 305-867, C: 868-
1507, D: 1508-1982 and E: 1814-1982). pDBT-c-Myb
encodes full-length human c-Myb in fusion with Gal4p-
DBD [25]. pGADT7-PIAS1[1-501] encodes amino acids
1-501 of human PIAS1 in fusion with the transactivation
domain of Gal4p, and was isolated in the two-hybrid
screening. pGADT7-PIAS1 encodes full-length human
PIAS1 in fusion with Gal4p-AD. pGEX-6p-2-FLASH-A
is encoding GST fused to the FLASH A fragment
(amino acid residues 1-304). pGEX-6p-2-FLASH-D is
encoding GST fused to the FLASH D fragment (amino
acid residues 1508-1982), while pGEX-6p-2-FLASH-D-
KR has the SUMO acceptor lysine K1813 mutated to
arginine. pHA-FLASH encoding full-length mouse
FLASH with HA-tag was kindly provided by Y.K. Jung
[61]. pCIneo-3×FLAG-FLASH encodes full-length
human FLASH with an N-terminal triple FLAG-tag.
pCIneo-3×FLAG-FLASH-D encodes amino acids 1508-
1982 of FLASH with an N-terminal triple FLAG-tag,
while pCIneo-3×FLAG-FLASH-D-K1813R encodes the
same part of FLASH with a K1813R mutation [45].
pGFP-FLASH encodes a GFP-FLASH fusion protein and
was a kind gift from V. De Laurenzi [5]. pCIneo-hcM
encodes human c-Myb [25]. pCIneo-hcM-HA-2KR
encodes human c-Myb with a C-terminal HA-tag and
with sumoylation sites K503 and K527 mutated to argi-
nine [25]. The expression vector pCIneoB-GBD2-hcM
[233-640]-HA, encoding a c-Myb protein lacking its
own DBD in fusion Gal4p-DBD, has been described
[26]. pCIneo-H6-hSUMO1 encodes human SUMO-1
with a N-terminal histidine tag. pGFP-SUMO-1 encodes
a GFP-SUMO-1 fusion protein and was kindly provided
by G. Del Sal [62]. pCIneoB-3×FLAG-PIAS1 and pCI-
neoB-3×FLAG-PIAS1 RING finger mutant encode
human PIAS1 wild-type and PIAS1 with RING finger
mutations (C346S/C351S/H353A/C356S), respectively,
both with an N-terminal triple FLAG-tag. pCMV5-
FLAG-PIAS1 and pCMV5-FLAG-PIAS1[C350S] encode
PIAS1 wild-type and a RING finger mutant, respectively.
Both have an N-terminal FLAG-tag and were kind gifts
from V. De Laurenzi [44]. pcDNA3-HA-hPIAS1 encodes
PIAS1 with an N-terminal HA-tag. The Myb-responsive
reporter plasmid pGL4b-3×MRE(GG)-MYC-aab con-
tains three Myb-responsive elements and core promoter
from MYC (P2 promoter) upstream the luciferase repor-
ter gene [26]. The Gal4p-responsive reporter plasmid
pGL3b-5×GRE-SNRPN is described in [29]. pCIneo-
GBD1-FLASH and pCIneo-GBD1-FLASH-KR encode
Gal4p-DNA-binding domain in fusion with full-length
wild-type FLASH [6] and FLASH-K1813R [45] respec-
tively. All constructs generated by PCR were verified by
sequencing. Primer sequences are available upon
request.
GST pulldown assays
GST, GST-FLASH-A, GST-FLASH-D and GST-FLASH-
D-KR were expressed in E. coli [29,63]. GST pulldown
was performed as described earlier in cell extracts from
transfected COS-1 cells [6]. The bound proteins were
eluted by boiling in SDS sample buffer, subjected to
SDS-PAGE, and detected by immunoblotting as
described earlier [6].
Cell culture and transient transfections
CV-1 and COS-1 cells were grown in DMEM (Invitro-
gen) supplemented with antibiotics, L-glutamine and
10% foetal bovine serum (FBS). HD11 cells were grown
in IMDM supplemented with antibiotics and 10% serum
(8% FBS and 2% chicken serum). K562 cells were culti-
vated in IMDM supplemented with 2 mM glutamax,
antibiotics and 10% FBS. All four cell lines were kept at
37°C in a humidified atmosphere of 5% CO2 in air.
Transient transfections were performed using FuGENE6
Transfection Reagent (Roche).
Immunoprecipitation
Transfected COS-1 cells (15-cm dishes; 2.5 × 106 cells/
dish; 1 dish per IP) were harvested 24 h after transfec-
tion in 150 μl of lysis buffer (400 mM NaCl, 1.0% Triton
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X-100, 10% glycerol, 50 mM Tris pH 8.0, 1 mM EDTA,
100 mM NaF, 1 mM MgCl2, 10 mM DTT, and Com-
plete Protease Inhibitor), debris was removed by centri-
fugation and the cleared lysate was diluted 1:4 in
dilution buffer (lysis buffer without NaCl and Triton
X-100). Then 600 μl of diluted lysate (100 mM NaCl,
0.25% Triton X-100, 10% glycerol, 50 mM Tris pH 8.0,
1 mM EDTA, 100 mM NaF, 1 mM MgCl2) was sub-
jected to immunoprecipitation with indicated antibodies
and protein G-Sepharose beads after a preclearing step
with G-Sepharose beads only. Immunoprecipitation was
performed on a roller at 4°C overnight. The beads were
washed three times in 500 μl of wash buffer (100 mM
NaCl, 0.25% Triton X-100, 10% glycerol, 50 mM Tris
pH 8.0, 1 mM EDTA, 100 mM NaF, 1 mM MgCl2), and
the proteins eluted in 40 μl SDS loading buffer for
4 min at 95°C. Proteins were separated by SDS-PAGE
and detected with immunoblotting.
Chromatin immunoprecipitation
Transfected HEK-293 cells, C#1 [41], were cross-linked
with 1% formaldehyde in PBS at room temperature for
15 min. Cross-linking was performed with rotation, and
the reaction was stopped by addition of glycine to a
final concentration of 125 mM. After two washes with
PBS, cells were lysed in IP buffer (50 mM Tris-HCl pH
7.5, 5 mM EDTA, 1% Triton, 0.5% NP-40, 150 mM
NaCl, 1.0% SDS and Complete Protease Inhibitor) and
frozen in LN2. After thawing the samples were diluted
to a final SDS concentration of 0.1%. Samples were soni-
cated to generate sheared DNA fragments around 400
base pairs (soluble chromatin fraction), and insoluble
chromatin was discarded after centrifugation. Dyna-
beads™ ProteinG were washed with PBS and incubated
with antibody at room temperature for 40 min followed
by washing with PBS. The soluble chromatin fraction
was then added followed by incubation overnight at 4°C
with rotation. Chromatin equivalent to 200 000 cells
was used per IP with 20 μl Dynabeads™ ProteinG and
2 μg antibody, in a total volume of 1.2 ml IP buffer. The
immunoprecipitates were washed five times in IP buffer,
before DNA was eluted with 1% SDS in 100 mM
sodium carbonate at 65°C for 10 min. After treatment
with RNAse A and proteinase K, cross-linking was
reversed by incubation at 65°C for 8 h. DNA was puri-
fied using silica columns (Macherey-Nagel) and eluted
in 50 µl 10 mM Tris-HCl [pH 7.5]. 2.5 µl of the eluted
DNA was used as template for quantitative real-time
PCR in a total volume of 20 µl (LightCycler® 480 SYBR
Green I Master, Roche Diagnostics). Standard curves of
genomic DNA were run alongside the ChIP samples for
each primer pair, and analyzed on a LightCycler® 480
(Roche Diagnostics). Input DNA was used to normalize
values from ChIP samples.
Antibodies
For Western immunoblotting the following antibodies
were used: rabbit anti-HA (H 6908, Sigma-Aldrich),
mouse anti-FLAG M2 antibody (F 3165, Sigma-Aldrich),
goat anti-PIAS1 (sc-8152, Santa Cruz), rabbit anti-PIAS1
(ab77231, Abcam) rabbit anti-GFP (ab6556, Abcam),
mouse anti-GAPDH (Biodesign International, Saco,
Maine), and mouse anti-tubulin (T9026, Sigma). Anti-
mouse IgG-HRP (NA 931, GE Healthcare Life Sciences),
anti-rabbit IgG-HRP (NA 934, GE Healthcare Life
Sciences), and anti-goat IgG-HRP (sc-2033, Santa Cruz)
were used as secondary antibodies. As immunofluores-
cence antibodies rabbit anti-HA (H 6908, Sigma-
Aldrich), mouse anti-FLAG M2 antibody (F 3165,
Sigma-Aldrich), and mouse anti-pol II (8A7, sc-13583,
Santa Cruz) were used. Alexa Fluor 488 goat anti-rabbit
IgG(H+L), Alexa 546 goat anti-mouse IgM(μ), and
Alexa Fluor 633 goat anti-mouse IgG1 (g1) (Molecular
Probes) were used as secondary antibodies.
Reporter gene assays
CV-1 cells were plated in 24-well microplates at a con-
centration of 2×104 cells per well the day before transfec-
tion. The cells were transfected with a total of 0.8 μg
DNA per well. Cells were washed twice in PBS, and lysed
in Passive Lysis Buffer (Promega) 24 hours after transfec-
tion. Luciferase activity was monitored with a Luciferase
assay kit (Promega). Light emission was determined with
a luminometer (Turner Designs). Each experiment was
performed in triplicate, and average data from three inde-
pendent transfection experiments are presented.
RNA isolation and quantitative RT-PCR
HD11 cells were transfected as described above with a
total of 5 µg DNA per well in 6-well microplates seeded
with 5×105 cells per well the day before. 24 hours after
transfection the cells were harvested and total RNA was
extracted with Trizol reagent (Invitrogen), followed by
DNase treatment and purification of the RNA using
RNeasy columns (Qiagen). 3µg of RNA for each sample
were used for reverse transcription using the Superscrip-
t™III system (Invitrogen). Two different dilutions of the
cDNA obtained were subjected to real-time PCR analy-
sis to determine the expression of the c-Myb target
gene mim-1, using the LightCycler DNA MasterPlus
SYBR Green Kit (Roche). A standard curve made from
serial dilutions of cDNA was used to calculate the rela-
tive amount of mim-1 mRNAs in each sample. These
values were normalized to the relative amount of the
reference gene HPRT in the same samples, calculated
from a standard curve established in the same way. The
cellular transfections were performed in triplicate and
the experiment was repeated three times. Primer
sequences are available upon request.
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RNA interference
RNA interference was performed as previously described
[29]. The K562 cells were transfected with FlexiTube
siRNA from Qiagen Hs_PIAS1_1 or Ctrl_Lucifera-
seGL2_2 at 5 pmol/sample. After 24 hour RNA were
isolated and analysed in quantitative RT-PCR, essentially
as described above. Target genes evaluated were PIAS1,
LMO2 and MYC, and as reference genes ACTB and
POLR2A. The primer sequences are available upon
request.
Immunofluorescence and confocal laser scanning
microscopy
1.8×104 CV-1 cells were plated out in 24-well microplates
containing cover-slips and transfected with a total of
0.6 μg DNA. 24 hours after transfection cells were
washed in PBS. Cells were fixed and permeabilized with
ice cold methanol for 5 min. Samples were washed three
times for 5 min in PBS containing 0.1% Tween 20, then
blocked for 30 min with 2% BSA in PBS with 0.1%
Tween 20, following incubation with primary antibodies
diluted 1:50 in the blocking solution for 45 min. Samples
were then washed three times as above, and incubated
with secondary antibodies diluted 1:100 in the blocking
solution for 30 min. Samples were washed three times
again and incubated with Hoechst 33258 (Sigma-Aldrich)
for 20 min to visualize DNA. Samples were washed once
in PBS containing 0.1% Tween 20, once in PBS and once
in dH2O. The cover-slips were then placed on micro-
scope slides using mounting medium (Dako). Cells were
examined using a FluoView laser scanning system from
Olympus. Images from the different channels were col-
lected sequentially to prevent bleed through.
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